Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects at Malta Conferences Foundation Online Event
On Wednesday, September 30, 2020, Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading Israeli regenerative medicine company developing a platform of novel biological products, and the Abu Dhabi Stem Cells Center (ADSCC) unveiled their first joint projects in a presentation at the Malta Conferences Foundation (MCF), a global conference supported by kENUP Foundation, a promoter of research-based innovation with public and societal benefit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005476/en/
Malta Conferences address shared desire to improve quality of life and political stability in Middle East through scientific collaboration (Graphic: Business Wire)
Pluristem and ADSCC presented new projects, part of the recently signed Memorandum of Understanding aimed at harnessing the power of regenerative medicine.
The first joint project brings together the expertise of Pluristem and ADSCC to advance a potential COVID-19 treatment. The project will involve the first-time administration of Pluristem’s PLX cells via a nebulizer, a drug delivery device that helps a patient inhale medication through a mask or mouthpiece, to COVID-19 patients. The collaboration allows ADSCC to expand their stem cell therapy options using Pluristem’s PLX cells, while enabling Pluristem to leverage ADSCC’s nebulizer administration experience to develop a new treatment delivery model for PLX cells. ADSCC has reported effectively using nebulizers to treat COVID-19 patients with stem cells sourced from the patient’s own blood.
Further discussions for additional projects are underway, including for potential collaboration in chronic Graft Versus Host Disease (cGvHD), a life-threatening immune response of the donor’s stem cells against the host (patient).
The parties presented the joint projects to a distinguished audience at the MCF, including Nobel Laureates, scientists, and diplomats. The foundation’s mission is to address the shared desire to improve quality of life and political stability in the Middle East by identifying opportunities for collaboration to meet the scientific and technological challenges of the region.
“I am delighted for the opportunity to convene this important meeting. The Malta Conferences are the only platform in the world where scientists from 15 Middle East countries, Morocco and Pakistan can get together under the same roof with several Nobel Laureates. They develop collaborations and friendship which overcome the chasms of distrust and intolerance.” said Prof. Zafra Lerman, President of Malta Conferences Foundation.
“Embarking on this journey with Pluristem to overcome one of this generation’s most complex medical challenges marks an exciting new chapter full of possibilities when it comes to knowledge sharing and medical innovation. Our partnership speaks volumes about the power of collaboration between partners across previously divided borders. While we simply do not yet know the long-term impact the novel coronavirus will have on recovered patients, by working together we believe we are able to leverage the best medical technologies and minds in the region to develop solutions to prevent and treat the lingering symptoms and long-term complications that are emerging.” said Dr. Yendry Ventura, General Manager of ADSCC.
“We were very honored to unveil our first joint projects with the ADSCC at the MCF. We see our partnership as a movement between Israel and the UAE, which we hope will lay the foundation for future collaborations that will help potentially bring change to our region and the world. As we work together to develop regenerative medicine for key unmet medical needs of benefit to patients around the world, we are excited for the future and its possibilities,” stated Pluristem CEO and President Yaky Yanay.
‘Two world-class players in cell therapy join forces and cooperate on the fight of COVID-19. May this courageous cooperation serve as an example to the world’, says kENUP Foundation’s Executive Chairman Holm Keller.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005476/en/
Contact information
Nynke Rozema
rozema@kenup.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pre-filled Syringe Presentation of BYOOVIZ®, Samsung Bioepis' Biosimilar to Lucentis (Ranibizumab), Gains European Approval2.12.2025 08:00:00 EET | Press release
Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for BYOOVIZ® pre-filled syringe (PFS), a biosimilar referencing Lucentis1 (ranibizumab). BYOOVIZ was first approved by the European Commission (EC) in August 2021 as a single use vial for intravitreal use (0.5 mg/0.05 ml) for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) and visual impairment due to choroidal neovascularization (CNV). The PFS presentation is regarded as the standard of care in ophthalmology, providing convenience for administration with precise dosing and ease of use with syringe injection, as well as safety benefits in the form of a decreased risk of endophthalmitis versus v
Oulu Launches Its European Capital of Culture Year with a Three-day Opening Festival2.12.2025 08:00:00 EET | Press release
The Oulu2026 Opening Festival on 16–18 January 2026 transforms the city centre into a vibrant celebration of culture, community and northern creativity. It marks the beginning of a historic year and invites residents, visitors and partners from Finland, Europe and beyond to take part in a unique moment for Oulu and its 39 partner municipalities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201071170/en/ In January, Oulu’s city centre will transform into the Oulu2026 Opening Festival area. Photo: Harri Tarvainen / City of Oulu image bank. “After years of preparation, Oulu2026 is finally here. The Opening Festival gives everyone a chance to be part of something that will only happen once, and it all begins in the heart of Oulu,” says Piia Rantala-Korhonen, CEO of Oulu2026. Almost 200 events, over 20 venues The Opening Festival presents a wide range of art and cultural experiences all over the city centre. From exhibitions
Murata Unveils World’s First 15nF/1.25kV C0G MLCC in 1210-inch Size2.12.2025 04:00:00 EET | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) announces the launch and mass production of its multilayer ceramic capacitor (MLCC) featuring a capacitance of 15nF, a rated voltage of 1.25kV, and C0G characteristics in the compact 1210-inch (3.2mm x 2.5mm) size. This product delivers highly efficient power conversion and stable performance under high-voltage conditions, making it suitable for onboard chargers (OBCs) in electric vehicles (EVs) and power supply circuits in high-performance consumer devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201104421/en/ [Murata Manufacturing Co., Ltd.] 15nF/1.25kV/C0G MLCC in 1210-inch Size Resonant and snubber circuits are essential for efficient power conversion and suppressing current and voltage peaks. In both circuits, repeated exposure to high voltage and high current can cause even slight changes in component performance, leading to efficiency loss or
With 40% of Agentic AI Projects Predicted to Fail, Leading Software Developer Says Compliance Is the One Place Where Agentic AI Will Thrive2.12.2025 02:01:00 EET | Press release
The CEO of one of the world’s leading global compliance software developers, Ideagen, has today (December 2, 2025) said compliance represents the one domain where autonomous AI will succeed – despite technology insights company Gartner® warning "… over 40% of agentic AI projects will be canceled by the end of 2027”. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201511477/en/ Ben Dorks, Ideagen CEO Speaking at the launch of their own agentic AI platform Ideagen Mazlan, Ben Dorks said: “Autonomous AI will succeed in compliance because failure is measurable, stakes are high and outcomes are binary. “AI that continuously monitors jurisdictional or industry specific compliance frameworks, detects patterns across thousands of records, raises actions for others to follow, flags gaps before audits, autonomously? That's agentic. It will literally save lives and is the most transformative shift in protecting people, products and p
VeriSilicon’s NPU IP VIP9000NanoOi-FS has Achieved ISO 26262 ASIL B Certification2.12.2025 02:00:00 EET | Press release
VeriSilicon (688521.SH) today announced that its NPU IP VIP9000NanoOi-FS has successfully achieved ISO 26262 ASIL B certification, marking a significant milestone in the functional safety capabilities of the company’s neural network processing unit portfolio. This IP features an architecture streamlined for seamless SoC integration, delivering high-quality inference with low power consumption and a compact silicon footprint. The certificate was issued by SGS-TÜV Saar, an international testing, inspection and certification institution. As part of VeriSilicon’s VIP9000 series, the VIP9000NanoOi-FS IP is designed for automotive and edge AI applications, providing high-performance neural network processing with a safety-compliant architecture. The IP supports a wide range of AI inferencing models including Large Language Models (LLMs) and Convolutional Neural Networks (CNNs), with hardware-accelerated AI inference, enabling real-time applications such as object and scene detection, augment
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom